Drugs / BOTOX-A

Trials 3

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT04991688 Sep 2021 → Jan 2023 — University Hospital, Bordeaux Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT01278576 Jan → Dec 2011 stroke disorder The Catholic University of Korea Completed No outcome recorded
Phase not applicable1 trial
— NCT06553950 Aug 2024 → Feb 2025 overdue temporomandibular joint disorder Cairo University Recruiting No outcome recorded
Comparator or background therapy2 trials
Phase 2 NCT00711087 Comparator Jul 2007 → Feb 2010 spinal cord injury, urinary bladder disorder Baylor College of Medicine Terminated No outcome recorded Stop: Business
Phase 2/3 NCT06676475 Comparator Dec 2024 → Feb 2025 overdue myofascial pain syndrome Misr University for Science and Technology Not yet recruiting No outcome recorded

Press releases naming this drug 12 releases

DateIssuerRelease
2026-05-19 Ipsen Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity ipsen.com ↗
2026-04-13 Cutia Therapeutics(Wuxi)Co.,Ltd VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE III CLINICAL TRIAL OF CU-20101 (BOTULINUM TOXIN TYPE A FOR INJECTION) FOR IMPROVING MODERATE TO SEVERE GLABELLAR LINES IN CHINA cutiatx.com ↗
2026-01-19 Cutia Therapeutics(Wuxi)Co.,Ltd VOLUNTARY ANNOUNCEMENT - CU-20101 (BOTULINUM TOXIN TYPE A FOR INJECTION) FOR IMPROVING MODERATE TO SEVERE GLABELLAR LINES ACHIEVED POSITIVE TOPLINE RESULTS FROM PHASE III CLINICAL TRIAL IN CHINA cutiatx.com ↗
2025-07-09 Evolus, Inc. Evolus Expands Global Footprint with Introduction of Nuceiva<sup>&reg;</sup> (botulinum toxin type A) in France evolus.com ↗
2024-07-30 Evolus, Inc. Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia evolus.com ↗
2024-06-12 Evolus, Inc. Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain evolus.com ↗
2023-06-29 Evolus, Inc. Evolus Launches Nuceiva® (botulinum toxin type A) in Italy evolus.com ↗
2021-02-10 AbbVie BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition abbvie.com ↗
2020-07-09 AbbVie FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity abbvie.com ↗
2020-06-22 AbbVie FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity abbvie.com ↗
2019-04-08 Evolus, Inc. Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal evolus.com ↗
2018-04-05 Evolus, Inc. Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint evolus.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as BOTOX-A “A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe.” NCT06553950 ↗
4

NCT00711087 ↗

NCT06676475 ↗

NCT01278576 ↗

NCT04991688 ↗

Known as BOTOX “Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90” NCT00711087 ↗
Known as Botulinum toxin type A “Botulinum toxin type A is a neurotoxin used to reduce excessive muscle contraction.” NCT06676475 ↗
Action Inhibit “When injected, the toxin acts at the neuromuscular junction of the external sphincter to block vesicle transport of acetylcholine” NCT00711087 ↗
Modality Protein / enzyme biologic “BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex” NCT00711087 ↗
Route Other “BTX-A injection of the external urethral sphincter” NCT00711087 ↗